Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 7 Issue: 5

Changes of Circulating Endothelial Cells and Microparticles after Conventional Chemotherapy in Patients with Extensive Small-Cell Lung Cancer: Relevance to Prognosis and Treatment Response

Najjar F1*, Alammar M2, Al-Massarani G1, Almalla N1, Japawe A3, Banat I1 and Ikhtiar A3

1Biomarkers Laboratory, Radiation Medicine Department, Atomic Energy Commission of Syria (AECS), Damascus, Syria

2Division of Thoracic Oncology, Oncology Department, Albairouni University Hospital, Duma, Syria

3Radiobiology laboratory, Biotechnology Department, Atomic Energy Commission of Syria (AECS), Damascus, Syria

*Corresponding Author : Najjar F
Biomarkers Laboratory, Department of Radiation Medicine, AECS, Damascus, Syria
Tel:
+963112132580
E-mail:
[email protected]

Received: August 16, 2017 Accepted: September 09, 2018 Published: September 16, 2018

Citation: Najjar F, Alammar M, Al- Massarani G, Almalla N, Japawe A, et al. (2018) Changes of Circulating Endothelial Cells and Microparticles after Conventional Chemotherapy in Patients with Extensive Small-Cell Lung Cancer: Relevance to Prognosis and Treatment Response. J Clin Exp Oncol 7:5. doi: 10.4172/2324-9110.1000228

Abstract

Objectives: Tumor angiogenesis is controlled by inhibitors and angiogenic factors. However, circulating endothelial cells (CECs) and microparticles (MPs) may be related to tumor angiogenesis in malignant tumors. We therefore investigated the significance of CECs and MPs variation for the prediction of treatment efficacy and
prognosis in patients with extensive small-cell lung cancer (SCLC). Materials and methods: Isolation and quantification of CECs from the whole-blood was performed using immune magnetic separation (IMS) technique, while flow cytometry measurement (FCM) was used for enumerating MPs in plasma samples.
Results: Twenty-six patients were included in this prospective study. The relative change in CEC and MP counts after treatment, correctly identified treatment response in 22/26 patients (84.6%) and 17/23 patients (73.9%) respectively. The difference in themedian duration of time to progression (TTP) between patient with high relative changes and those with low relative changes in CEC and MP values was not statistically significant (p=0.39 and p=0.2, respectively). By contrast, the increase in CEC and MP levels after chemotherapy tended to be inversely correlated with longer TTP duration (r²=0.111 and r²=0.171, respectively). However, onlym decreased MP values after chemotherapy have the trend to be correlated with longer TTP duration (r²=0.167).
Conclusion: The relative change in CEC and MP values after treatment seems to be a useful biomarker for the evaluation of treatment response in patients with extensive SCLC. Moreover, this relative change in both biomarkers might be considered as a prognostic tool in SCLC.

Keywords: Biomarker; Circulating endothelial cells; Microparticles; Prognosis; small-cell lung cancer; Survival; Treatment response.

Track Your Manuscript

Share This Page

Media Partners